Sign in

Izabela Zakrocka

@izabelazakrocka.bsky.social
993 followers 837 following 51 posts

Internist, nephrologist, transplantologist, Assistant Professor at Medical University of Lublin, #Glomcon 2021-2022 Fellow, ERA YNP Representative of Poland 🇵🇱, Board of Polish Young Transplantologists #NephSky #KidneyOmics #PharmKidney

PostsRepliesMedia
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 02/10/2026
interesting title of the day pubmed.ncbi.nlm.nih.gov/36590677/
382
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 02/10/2026
10 cups of coffee a day can give you…..a nasty kidney stone www.kidney-international.org/article/S008... in @kidneyint.bsky.social
Picture of the kidney stone
1105
Reposted by Izabela Zakrocka
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 01/10/2026
Interesting report. But all 4 donors had overt proteinuria at the time of organ allocation. Is it standard procedure to ignore that in deceased kidney donation? Tapping a transplantologist @georginairish.bsky.social @nymurakami.bsky.social #NephSky
144
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 25/09/2026
Josh @pulmcrit.bsky.social tackles ICU management of DAH incl ANCA vasculitis emcrit.org/ibcc/dah/#tr... On PLEX: yes that doesn’t help DAH at all However, in some patients, it helps save a few months off dialysis - small effect #NephSky #emimcc
emcrit.org
Pulmonary vasculitis & diffuse alveolar hemorrhage (DAH)
CONTENTS Diffuse Alveolar Hemorrhage (DAH) Clinical presentation Radiology Bronchoscopy Causes Evaluation Management ANCA-associated vasculitis (GPA & MPA) Definitions Clinical features Laboratory fin...
174
Reposted by Izabela Zakrocka
Yale Nephrology @yalenephrology.bsky.social · 13/08/2026
How do B cells survive the hypertonic kidney in lupus nephritis? At Medical Grand Rounds, Dr. Irene Chernova took us from the γ subunit of the Na-K-ATPase to extracellular ATP signaling via P2RX4 and P2RX7. Genuinely surprising axis & terrific discussion. Excited for what's next!
0106
Reposted by Izabela Zakrocka
ASN Publications @asnpublications.bsky.social · 02/08/2026
#ASNKidney360 review: Could post-transplant anti-GBM nephritis be the Achilles’ heel of kidney transplantation in Alport syndrome, affecting ~5% of patients and causing rapid allograft loss with recurrence after re-transplantation? kidney.pub/KID1310?u...
053
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 02/08/2026
ZEUS thunderbolt does not land uk.finance.yahoo.com/news/novo-no... Need to see full data at #KidneyWk - treating just inflammation likely doesn’t make sense
uk.finance.yahoo.com
Novo Nordisk provides update on the ZEUS phase 3 trial in people with ASCVD, CKD and inflammation
Bagsværd, Denmark, 31 July 2026 – Novo Nordisk today announced headline results from the ZEUS cardiovascular outcomes phase 3 trial. While ziltivekimab demonstrated target engagement and inhibition of...
1112
Reposted by Izabela Zakrocka
Jonathan Zuckerman MD PhD @jzrenalpath.bsky.social · 31/07/2026
Fibrin extravasating into Bowman's capsule in this case of MPO-ANCA associated pauci immune GN. Destructive necrotizing cellular crescent. Prominent necrotizing arteritis as well. #renalpath #pathsky #nephsky
086
Reposted by Izabela Zakrocka
Jonathan Zuckerman MD PhD @jzrenalpath.bsky.social · 31/07/2026
Another interesting case with crescents but this time due to amyloid. A few small cellular crescents in this case of AL-amyloidosis. Massive capillary wall amyloid infiltration. #renalpath #pathsky #nephsky
075
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2026
Guidance on nutrition supplementation in dialysis www.kireports.org/article/S246... In @kireports.bsky.social Increasing protein intake once dialysis begins is important!
Algorithm
1119
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 31/07/2026
Note this means higher clearance of biomarkers with HDF, not that HDF causes less cardiac injury journals.lww.com/kidney360/pd... In #Kidney360 @asnpublications.bsky.social
journals.lww.com
192
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 27/07/2026
The Thermo Fisher western blot story www.chemistryworld.com/news/thermo-... This looks very bad.
chemistryworld.com
Thermo Fisher antibody data manipulation is a breach of trust, say researchers
Science sleuths say the problem is impacting research progress and Thermo's response falls short
054
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 27/07/2026
IgAN in South Asia - nice editorial (review) in @kireports.bsky.social www.kireports.org/article/S246... Much more common than thought (underdiagnosed till recently) and leads to other caveats
kireports.org
IgAN in South Asia
The prevalence of chronic kidney disease (CKD) in South Asia is 6.46%, compared with a global median prevalence of 9.5%.1 Despite this, the region accounts for more than 20% of the global CKD burden b...
094
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 27/07/2026
Ooh @kidneyint.bsky.social goes there Fast www.kidney-international.org/article/S008... Slow www.kidney-international.org/article/S008... Hyponatremia controversies #NephSky
kidney-international.org
Hyponatremia treatment guidelines: a necessary course correction
The optimal treatment of hyponatremia has been debated for >50 years. It is now widely accepted that in severe hyponatremia (<120 mmol/L), the rate of correction should not exceed 8 mmol/L per 24 hour...
1136
Reposted by Izabela Zakrocka
kireports.bsky.social @kireports.bsky.social · 28/07/2026
#Outcomes and #Predictors of Treatment #Response in Patients With Pure #Lupus Membranous #Nephropathy #VisualAbstract by Kajaree www.kireports.org/article/S2468-024…
074
Reposted by Izabela Zakrocka
Juan Carlos Q Vélez, MD @juancarlosqvelez.bsky.social · 28/07/2026
Huge step in the right direction. Serological anti-NELL1 antibodies are necessary to improve the diagnosis and management of NELL1-membranous nephropathy #NephSky
085
Reposted by Izabela Zakrocka
Science Magazine @science.org · 09/07/2026
A #ScienceTranslationalMedicine study of T cells from patients with #lupus nephritis shows these cells are activated by local cytokines and could mediate injury in inflamed kidneys, with some T cells reactive to potentially latent Epstein-Barr virus and cytomegalovirus. scim.ag/4w0m54w
scim.ag
Cytokine-mediated activation of kidney-infiltrating CD8+ T cells enables their contribution to inflammation in human lupus nephritis
Kidney-infiltrating CD8+ T cells in human lupus nephritis are activated via local cytokines and have the capacity to amplify local inflammation.
0307
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 08/07/2026
The bladder is often scarred or shrunk in ESRD here’s a first in human feasibility report of a combined kidney bladder transplant www.thelancet.com/journals/lan... in @thelancet.com
Figure 2. Back-table preparation of the vascularised composite bladder allograft, creating a single arterial inflow and a single venous outflow supplying the entire bladder
043
Reposted by Izabela Zakrocka
Phil Riley @drphilriley.bsky.social · 27/06/2026
Whoa! A Beta-blocker ROSETTA STONE!! #CardioSky #MedSky www.jacc.org/doi/epdf/10....
jacc.org
Selective Use of Nonselective Beta-Blockers: A Tailored Antiarrhythmic Approach
View all available purchase options and get full access to this article.
242
Reposted by Izabela Zakrocka
kireports.bsky.social @kireports.bsky.social · 25/06/2026
German Clinical Practice #Guideline on #Microhematuria in #Children and #Young #Adults: Evaluating Early Detection of Kidney Disease doi.org/10.1016/j.ekir.2026.106495 #KIRGuidelines
053
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 19/06/2026
What we cannot dialyse Nicely written @ajkd.bsky.social www.ajkd.org/article/S027...
In a few words
0185
Reposted by Izabela Zakrocka
Gregor Bond @gregorbond.bsky.social · 04/06/2026
First data of the TTVguideIT RCT presented @ERA26 in Glasgow 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Personalized Immunosuppression 💊 by Torque Teno 🦠 virus in kidney TX is safe and might help reducing Tacrolimus #TTVguide @fredhaupenthal.bsky.social 👏
084
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 04/06/2026
Unlike COMPASS, TRACK demonstrates rivaroxaban doesn’t have the same CV benefit in CKD jamanetwork.com/journals/jam... Simultaneous pubs from #ERA26
jamanetwork.com
Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease
This randomized clinical trial examines the safety and efficacy of low-dose rivaroxaban in the treatment of patients with advanced chronic kidney disease at high risk for cardiovascular events.
1158
Reposted by Izabela Zakrocka
Michael S. Balzer @balzer-lab.org · 04/06/2026
🙏Feeling very grateful. Honored to receive the #ERA26 Stanley Shaldon Award from @ERAKidney. Thank you to everyone who has contributed to this journey! Our mission remains to better understand kidney repair/regeneration & translate these discoveries into new therapies for patients🩺🧪 #Nephsky #Medsky
Michael S. Balzer receiving the #ERA26 Stanley Shaldon Award from ERA President Roser Torra.
0112
Reposted by Izabela Zakrocka
American Journal of Kidney Diseases @ajkd.bsky.social · 30/05/2026
NEW on the #AJKDBlog: @maximalchange.bsky.social interviews Jia Wei Teh and Michelle O’Shaughnessy about complement inhibition in Immunoglobulin A Nephropathy (IgAN):
bit.ly
Complement Inhibition in IgAN: An Interview
IgA nephropathy (IgAN) is the most common immune-mediated glomerular disease worldwide. Advanced understanding of the role of complement in IgAN pathogenesis has motivated the development of comple…
032
Reposted by Izabela Zakrocka
Dominique Guerrot @dguerrot.bsky.social · 31/05/2026
Important metaanalysis presented at #ESH2026 & in The Lancet: In patients with CKD, each 5 mmHg reduction in systolic BP reduced major cardiovascular events by ~9%, with similar relative benefits across CKD stages, proteinuria status and baseline BP levels. linkinghub.elsevier.com/retrieve/pii...
093
Reposted by Izabela Zakrocka
Madhu Pai, MD, PhD @madhupai.bsky.social · 12/05/2026
My @thelancet.com review of @johngreensbluesky.bsky.social's book 'Everything is Tuberculosis' www.thelancet.com/journals/lan...
thelancet.com
The injustice of tuberculosis
Why would John Green, a best-selling American novelist, write a book about tuberculosis? The answer can be found in his new book Everything is Tuberculosis: The History and Persistence of Our Deadlies...
2247
Reposted by Izabela Zakrocka
Adam Schwarz @adamjschwarz.bsky.social · 09/05/2026
Hungary’s parliament sings “Ode to Joy” — the anthem of Europe — after Péter Magyar is sworn in as prime minister. Hungary is once again a proud member of the European Union.
621263696116
Reposted by Izabela Zakrocka
Brian Rifkin @brianrifkin.bsky.social · 02/05/2026
🚨A new KI Reports Community blog about Obinutuzumab. Wonderful review of how it differs from other anti-CD20 treatments, worth a read 📖 By Dr. Priyadarshini John #NephSky #MedSky www.kireportscommunity.org/post/beyond-...
kireportscommunity.org
Beyond Rituximab: Obinutuzumab Redefines Treatment in Resistant Membranous Nephropathy
Written by Priyadarshini John, DMPrimary membranous nephropathy (MN) is a prototypical autoimmune glomerular disease and one of the most common causes of nephrotic syndrome in adults. The discovery of...
084
Reposted by Izabela Zakrocka
Roman-Ulrich Müller @muellerrom.bsky.social · 02/05/2026
ADPKD comes with increased risk of aneurysms. This manifestation comes concern, for both patients and MDs. Risk assessment? Screening? Treatment decisions? This ERA Genes&Kidney commentary provides fin-depth guidance based on the @kdigo.org ADPKD guideline. academic.oup.com/ndt/article/...
academic.oup.com
KDIGO 2025 Clinical Practice Guideline for ADPKD: a commentary on intracranial aneurysms and other vascular manifestations from the ERA Working Group Genes & Kidney
Abstract. The 2025 KDIGO Clinical Practice Guideline for Autosomal Dominant Polycystic Kidney Disease (ADPKD) addresses intracranial aneurysms (ICAs) and o
0114
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 20/04/2026
indeed - why-dralazine say no to hydr-ANCA-zine! #NephJC
051
Reposted by Izabela Zakrocka
Nephrology Journal Club @nephjc.bsky.social · 20/04/2026
Do you prescribe hydralazine? Or, do you 🛑 it as soon as you see it? Hydralazine persists despite TID dosing & risks like... vasculitis 🔥 Are you asking Why-dralazine? ✅The blog by @dramiliflores.bsky.social @nephroseeker.medsky.social #NephSky www.nephjc.com/news/hydralazine-anca-vasculitis
nephjc.com
Why-dralazine?! Population risk of drug induced vasculitis — NephJC
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide i...
397
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 17/04/2026
Cool study - an amp of sodium bicarbonate (50 ml 8.4%) raises sodium similar to a boils of 3% - as expected of course! pubmed.ncbi.nlm.nih.gov/41937305/ @pulmcrit.bsky.social @kidneyboy.bsky.social #nephsky #emimcc
pubmed.ncbi.nlm.nih.gov
Comparison of 8.4% Sodium Bicarbonate vs. 3% Sodium Chloride in Severe Hyponatremia: A Retrospective Cohort Study - PubMed
This study found that a single 50 mL dose of HTB more often resulted in obtainment of guideline-recommended post-intervention serum sodium goal concentrations than a 100 mL HTS dose. Additional studies...
2158
Reposted by Izabela Zakrocka
Grace Choung, MD 박영이 @gracechoung.bsky.social · 18/04/2026
It's not always just diabetic GS Case of diabetic GS with chronic TMA 2/2 tyrosine kinase inhibitor (TKI) 🔸Anti-VEGF effects 🔸Most within weeks to months after starting TKI 🔸TMA +/- PAS+ pseudothrombi pmc.ncbi.nlm.nih.gov/articles/PMC... pubmed.ncbi.nlm.nih.gov/19054798/ #renalpath #pathsky
154
Reposted by Izabela Zakrocka
Edgar V. Lerma 🇵🇭 @edgarvlermamd.medsky.network · 18/04/2026
Proposed algorithm for the application of rituximab in minimal change disease (MCD) and primary focal segmental glomerulosclerosis (FSGS) ca. 2020 #Nephpearls #NephSky 👉 pubmed.ncbi.nlm.nih.gov/32942039/
054
Reposted by Izabela Zakrocka
Nephgirlsketches @nephgirlsketch.bsky.social · 18/04/2026
#BlueSkyArtShow #Nephsky
0123
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 15/04/2026
Is targeted release budesonide really free of systemic steroid action? In the CKJ academic.oup.com/ckj/article/... Adrenal insufficiency after Nefecon withdrawal
Targeted-release budesonide dose tapering with reported adverse effects. HbA1c: haemoglobin A1C; WBC: white blood cells; URTI: upper respiratory tract infection.
293
Reposted by Izabela Zakrocka
American Journal of Kidney Diseases @ajkd.bsky.social · 06/04/2026
Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review bit.ly/4rb5B6P (OPEN ACCESS)
The schematic diagram compares traditional versus precision medicine approaches to the treatment of FSGS. By categorizing FSGS into subtypes based on non-invasive molecular and genetic profiling, precision medicine enables initiation of disease modifying therapy that targets the injury pathway activated in an individual patient together with non-specific renoprotective drugs. This combined treatment regimen will increase the likelihood of a treatment response and achieve improved kidney health outcomes compared to sequential prescription of renoprotective agents followed by empirical immunosuppressive therapy (IST). Created with BioRender.com
041
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 02/04/2026
Spoke with the HCP Live folks about the WHO lead HEARTS program for BP control, based on the talk at #ISNWCN see it here
hcplive.com
Bridging the Gap in Hypertension Care Delivery, With Swapnil Hiremath, MD, MPH | HCPLive
Hypertension drives millions of preventable deaths, yet control lags globally. The HEARTS framework offers practical, scalable solutions to close this gap.
0113
Reposted by Izabela Zakrocka
Nephrology Journal Club @nephjc.bsky.social · 03/04/2026
🚨 #NephJC short 🩳from @kidneyboy.bsky.social The PUSH trial! 😉Can a wink, a nudge & a push encourage kidney stone formers to drink more fluid to prevent recurrence 🪨? (Hint: have 💦 behavioral trials worked in CHF or PCKD?) #NephSky #MedSky www.nephjc.com/news/2026/4/2/nephjc-short-the-push-trial
nephjc.com
NephJC Short: The Push Trial — NephJC
Water, water everywhere. Can a wink, a nudge and a push increase water intake to decrease kidney stone formation?
069
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 28/03/2026
Don’t stop RASi for the creatinine bumps Permissive Hypercreatinjnemia FTW In JNO, observational study PS matched, caveats apply jamanetwork.com/journals/jam...
Figure 2.  Kaplan-Meier Curves of the Cumulative Probability of the Primary Outcomes in the Propensity Score–Matched Cohort for All-Cause Mortality and End-Stage Kidney Disease
274
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 28/03/2026
Interesting trial in @kidneyint@bsky.social www.kidney-international.org/article/S008... SLE with remission. No symptoms. When dsDNA becomes positive (or doubles) do you preemptively increase immunosuppression? #NephSky #RheumSky
Figure 2 Survival at 24-month from randomization free of (A) renal flares, (B) extra-renal flares and (C) overall clinical flares in lupus nephritis patients presenting with asymptomatic serological reactivation and randomized to receive pre-emptive treatment (PT Group) or observant management (Control Group).
164
Reposted by Izabela Zakrocka
Kidney International @kidneyint.bsky.social · 20/03/2026
Commentary The expanding role of complement inhibitors in the treatment of IgA nephropathy doi.org/10.1016/j.kint.2025.12.015 Original article: doi.org/10.1016/j.kint.2025.11.017 #MedSky #NephSky #IgAN @ucm.es
033
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 16/03/2026
What is the actual risk of vasculitis with hydralazine aka #HydrANCAzine? Ottawa colleagues say ~ 20% higher risk vs RASi but overall very low absolute risk jamanetwork.com/journals/jam... in JNO
Figure of risk of vasculitis with hydralazine
173
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 14/03/2026
Striking image www.kidney-international.org/article/S008... Case report from my Ottawa colleagues in the Kidney International
Figure 2 Computed tomography of the patient’s abdomen and pelvis, showing the peritoneal dialysis catheter coiled in a left inguinal hernia.
071
Reposted by Izabela Zakrocka
Swapnil Hiremath 🍁🇨🇦 @hswapnil.medsky.social · 14/03/2026
Yet another ddAVP trial for kidney biopsies with neutral results academic.oup.com/ckj/advance-... In Clinical Kidney Journal Previous #NephJC discussion: www.nephjc.com/news/ddavp
academic.oup.com
Bleeding prevention with desmopressin for allograft kidney biopsies: a double-blind randomized study
AbstractBackground. Percutaneous kidney allograft biopsy is essential for evaluating graft dysfunction, but post-procedural bleeding remains the most frequ
142
Reposted by Izabela Zakrocka
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 11/03/2026
and a little press release from @columbiauniversity.bsky.social www.cuimc.columbia.edu/news/new-dis... @columbiakidney.bsky.social @isgd.bsky.social @cuimcglomcenter.bsky.social @glomcon.org
cuimc.columbia.edu
New Discovery May Improve Kidney Disease Diagnosis in Black Patients
A closer examination of the APOL1 gene in Black patients with kidney disease can provide more precise diagnoses than current protocols.
011
Reposted by Izabela Zakrocka
Simone Sanna-Cherchi 🧬 @genetickidneydoc.bsky.social · 11/03/2026
Online today on @jamanetworkopen.com our new paper on the role of #APOL1 M1 in increasing precision diagnosis for CKD in individuals from African ancestry. Collaboration with @kidneyomicsamps.bsky.social @gbadegesinlab.bsky.social @kirylukk.bsky.social et al jamanetwork.com/journals/jam...
jamanetwork.com
Precision Diagnosis in APOL1 Kidney Disease With p.N264K M1 Protective Variant
This case-control study evaluates whether, in patients with APOL1 high-risk genotype kidney disease with at least 1 G2 allele, M1 can distinguish APOL1 chronic kidney disease from non-APOL1 chronic ki...
194
Reposted by Izabela Zakrocka
Iain Bressendorff, MD PhD @ibressendorff.bsky.social · 08/03/2026
Is anyone using obinutuzumab for maintenance in SLE (I know there is no data)? Have young pt with LN III/IV, MMF + prednisone induction. Doing well, but persistently high dsDNA, C3/C4 normal. @kidneydoc101.bsky.social @juancarlosqvelez.bsky.social @kronbichlerlab.bsky.social @grahamabra.bsky.social
254
Reposted by Izabela Zakrocka
haysamrady @sodatroubles.bsky.social · 05/03/2026
SGLT2 inhibitors in adult patients with Alport Syndrome #nephsky #nephrology www.kireports.org/article/S246...
kireports.org
SGLT2-inhibitors in adult patients with Alport Syndrome
Alport syndrome (AS) is a genetically heterogenous kidney disease characterised by microhaematuria, proteinuria, and progressive chronic kidney disease (CKD). Although early renin-angiotensin system i...
032